跳至主要内容
临床试验/ACTRN12615000350527
ACTRN12615000350527已完成2 期

For survivors of stroke/TIA experiencing self-reported persistent fatigue, will modafinil be more effective than placebo for reducing self-reported fatigue levels and increasing physical activity levels

Hunter-New England Local Health District0 个研究点目标入组 36 人开始时间: 2015年4月17日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
入组人数
36

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Blinded (masking used)

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • 1: have suffered an ischaemic stroke or TIA at least 3 months ago
  • 2: have persistent self-reported fatigue with MFI-20 score of 12 or more
  • 3: modified Rankin Score (mRS) of 3 or less
  • 4: can speak reasonable English, understand instructions and be able to complete tests and questionnaires on their own or with minimal support
  • 5: able to give informed consent

排除标准

  • 1: pre-existing depression, dementia or other neuropsychiatric disease
  • 2: other diagnoses with fatigue as a known symptom e.g. chronic fatigue syndrome, multiple sclerosis
  • 3: stroke induced by trauma, infection or surgery
  • 4: current or past drug abuse
  • 5: known contraindication to treatment with modafinil
  • 6: known active malignancy, any intracranial tumor, subdural or epidural hematoma
  • 7: known contraindications to MRI scanning e.g. claustrophobia, pacemaker or other implants
  • 8: renal or hepatic impairment
  • 9: use of benzodiazepines or antiepileptic drugs
  • 10: patients on immunosuppression or known immunodeficiency state e.g. HIV

研究者

相似试验